OPN
Openn Negotiation Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-26.64%
Annual Growth
3 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
9
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Openn Negotiation Ltd. engages in buying and selling of real estate properties. The firm is an online auction and property sales platform. The firm offers a cloud-based software platform to support real estate agents in selling property online. The firm's primary business is the operation of the Platform, which enables the listing and sale of residential real estate online utilizing the Openn Negotiation Process. The business services the Australian and New Zealand residential property markets. Its Platform facilitates a negotiation process, featuring streamlined digital contracting and automated communication tools. Its solution provides buyers with real-time feedback through their device on how much competition exists and where their price stands in the negotiation, providing transparency to the sales transaction process. The firm offers Openn Offers to provide another real estate sales method, which follows a typical private treaty sales process.
📈 Performance
Price History
-85.00%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.03
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in OPN
9
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in OPN
670 days
OPN investor breakdown
💵 Income of investors
More than 200k
150k - 200k
9%
100k - 150k
36%
50k - 100k
27%
Less than 50k
27%
👶 Age of investors
18 - 25
26 - 34
56%
35 - 90
44%
🙋 Legal gender of investors
Female
67%
Male
33%
Pearlers who invest in OPN also invest in...
VTS.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard U.S. Total Market Shares Index ETF seeks to track the performance of the CRSP US Total Market Index, providing investors with exposure to a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
📊 Share price
$320.13 AUD
NULL US
NULL EX AUSTRALIA
NULL BETA
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
📊 Share price
$90.18 AUD
NULL AUSTRALIA
NULL BETA
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
📊 Share price
$57.36 AUD
NULL GLOBAL
NULL SMART BETA
VEU.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard All-World ex-US Shares Index ETF seeks to track the return of the FTSE All-World ex US Index before taking into account fees, expenses and tax
📊 Share price
$82.10 AUD
NULL GLOBAL
NULL OTHER
NULL EX US
NULL BETA
CRYP.AX was created on 2021-11-02 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. CRYP.AX aims to track the performance of an Index (before fees and expenses) that provides exposure to global companies at the forefront of the crypto economy.
📊 Share price
$2.75 AUD
Want more shares? Try these...
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. The company also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
📊 Share price
$0.62 AUD
Openpay Group Ltd. is a payments technology company that offers a buy now, pay later product. The company is headquartered in Melbourne, Victoria. The company went IPO on 2019-12-16. The firm delivers an omnichannel financing solution that offers buy now pay later (BNPL) payment solutions in the form of next generation BNPL 2.0 product. Its BNPL 2.0 provides the gateway to complete transactions with payback terms of up to 24-months, across underserved BNPL verticals, including automotive, healthcare, home improvement, memberships, education, and retail. The Company’s B2B (business to business) offers OpyPro, a Software as a service (SaaS) based platform that allows companies to manage trade accounts end-to-end, including applications, credit checks, approvals and account management in the one system. The firm provides services to customers and merchants in Australia, New Zealand, the United Kingdom and United States.
📊 Share price
$0.20 AUD
Ophir High Conviction Fund is a AU-based company operating in industry. The company is headquartered in Sydney, New South Wales and currently employs 0 full-time employees. The company went IPO on 2018-12-19. Ophir High Conviction Fund is an Australia-based small and mid-cap equities fund. The Fund’s investment objective is to invest in approximately 15-30 companies listed outside the S&P/Australian Securities Exchange (ASX) 50. The Fund may also invest in international equities, such as listed securities in New Zealand, in accordance with the product disclosure statement and the provisions of the Fund's Constitution. The company invests in various sectors, including communication services, consumer discretionary, consumer staples, energy, financials, health care, industrials, information technology, materials, real estate, and utilities. Ophir Asset Management Pty Ltd is the responsible entity and manager of the Company.
📊 Share price
$2.39 AUD
OPL
Opyl Ltd. is an information technology company. The company is headquartered in St Kilda, Victoria. The company has two core business streams: services and technologies. Its technology research and development pipeline provide life science developers and healthcare providers with unprecedented insight and data optimization opportunities. The company has three key platforms in development that utilize artificial intelligence to analyze structured and unstructured data to deliver high value insights. Its platforms include clinical trial prediction and protocol design tool, clinical trial recruitment tool (Opin) and deep social media insights in healthcare. Its core services accessible at it include clinical trial recruitment, social media insights, market research and analysis and training and workshops. Its Opin is a clinical trial recruitment platform.
📊 Share price